Genzyme multiple sclerosis drugs

Genzyme continues to build the large late-stage data package for teriflunomide, an oral multiple sclerosis drug that the company and its

At the time, Genzyme was conducting clinical trials of a promising multiple sclerosis treatment called Lemtrada. Genzyme's shareholders didn

But the major driver was Genzyme's drugs for multiple sclerosis, with sales more than doubling to $285 million for the second quarter. In

treatment of active, relapsing multiple sclerosis (MS). Administration Genzyme's Lemtrada approved in Argentina for treatment of multiple sclerosis

Sanofi match HLA alleles with multiple sclerosis and associated drug Sanofi Genzyme drug Lemtrada (alemtuzumab) on MS patients, Liu said.

Genzyme continues to build the large late-stage data package for teriflunomide, an oral multiple sclerosis drug that the company and its

drugs (OR.80) were significantly Sanofi-Genzyme. Primary Source. European Committee for Treatment and Research in Multiple Sclerosis.

Lemtrada, the multiple sclerosis drug manufactured by Sanofi's Genzyme unit, is far and away the most cost-effective treatment for the

European Commission Approves Genzyme's Multiple Sclerosis Treatment LemtradaTM (alemtuzumab), 2024.